PEAK6’s Cytokinetics CYTK Stock Holding History

PEAK6’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,300	Closed	-$52.2K	–	3070
2025 Q1	$52.2K	Hold	1,300	–	–	﹤0.01%	2685
2024 Q4	$61.2K	Buy	+1,300	New	+$67.5K	﹤0.01%	2810

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PEAK6's CYTK Position: Q2 2025 in Review

PEAK6 sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 1,600 shares — an estimated $55.7K sold.

PEAK6 first reported a position in CYTK in Q4 2024 and held it in 2 quarters. The position peaked at $175K in Q4 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

PEAK6 reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
PEAK6 sold 1,600 Cytokinetics shares in Q2 2025, an estimated $55.7K.
PEAK6 first reported a position in Cytokinetics in Q4 2024 and held it in 2 quarters.
PEAK6's Cytokinetics position peaked at $175K in Q4 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on PEAK6's 13F filing for Q2 2025, filed 14 Aug 2025.